Published in Metabolites on May 17, 2013
The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer. BMC Cancer (2015) 0.81
Nanoparticle-Assisted Removal of Protein in Human Serum for Metabolomics Studies. Anal Chem (2015) 0.79
Metabolic Study of Breast MCF-7 Tumor Spheroids after Gamma Irradiation by (1)H NMR Spectroscopy and Microimaging. Front Oncol (2016) 0.75
Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites (2017) 0.75
Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells. Metabolites (2017) 0.75
On the origin of cancer cells. Science (1956) 49.55
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem (2006) 4.36
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem (1995) 3.61
Metabolic profiles of cancer cells. Nat Rev Cancer (2004) 3.21
NMR spectroscopy: a multifaceted approach to macromolecular structure. Q Rev Biophys (2000) 2.98
Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn (2008) 2.51
Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev (2010) 2.50
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst (2009) 2.49
Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs (2003) 2.35
Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res (2009) 2.10
Weak alignment NMR: a hawk-eyed view of biomolecular structure. Curr Opin Struct Biol (2005) 2.02
The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.96
Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem Biophys Res Commun (2003) 1.94
Nuclear magnetic resonance spectroscopy of high-molecular-weight proteins. Annu Rev Biochem (2004) 1.84
NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol (2008) 1.77
Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw (2009) 1.63
The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS One (2007) 1.60
Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal Biochem (2008) 1.51
Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev (2010) 1.51
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia (2009) 1.50
Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res (2010) 1.42
The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics (2005) 1.41
Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res (2011) 1.41
Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res (2010) 1.40
NMR in drug discovery. Nat Rev Drug Discov (2002) 1.40
GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res (2010) 1.39
The comparison of plasma deproteinization methods for the detection of low-molecular-weight metabolites by (1)H nuclear magnetic resonance spectroscopy. Anal Biochem (2002) 1.38
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36
Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One (2011) 1.35
An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res (2007) 1.34
Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res (2010) 1.30
Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood (1997) 1.28
Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One (2009) 1.28
Metabolomics: towards understanding traditional Chinese medicine. Planta Med (2010) 1.24
Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res (2012) 1.21
Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics (2010) 1.21
HR MAS MR spectroscopy in metabolic characterization of cancer. Curr Top Med Chem (2011) 1.19
Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. Phytochem Anal (2009) 1.18
Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues. Anal Biochem (2003) 1.12
Current metabolomics: practical applications. J Biosci Bioeng (2013) 1.12
Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed (2009) 1.11
Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. ACS Chem Biol (2011) 1.11
NMR-based screening in drug discovery. Q Rev Biophys (1999) 1.10
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist (2001) 1.10
Body fat free mass is associated with the serum metabolite profile in a population-based study. PLoS One (2012) 1.04
Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med (2012) 1.04
Urine metabolomics. Clin Chim Acta (2012) 1.02
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res (2011) 0.99
Metabolomics platforms for genome wide association studies--linking the genome to the metabolome. Curr Opin Biotechnol (2012) 0.99
Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol (2012) 0.99
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer (2007) 0.98
Evaluation of full-resolution J-resolved 1H NMR projections of biofluids for metabonomics information retrieval and biomarker identification. Anal Chem (2010) 0.97
Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. PLoS One (2011) 0.94
Quantitative two-dimensional HRMAS 1H-NMR spectroscopy-based metabolite profiling of human cancer cell lines and response to chemotherapy. Magn Reson Med (2010) 0.93
(1)H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system. J Biomol NMR (2011) 0.93
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol (2012) 0.92
Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem (2007) 0.92
Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol (2012) 0.92
Potential of human saliva for nuclear magnetic resonance-based metabolomics and for health-related biomarker identification. Anal Chem (2009) 0.91
Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy. J Oncol (2011) 0.91
Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol (2010) 0.89
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther (2011) 0.89
Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat (2009) 0.89
Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy. Metabolomics (2010) 0.88
Revealing the metabonomic variation of EC using ¹H-NMR spectroscopy and its association with the clinicopathological characteristics. Mol Biol Rep (2012) 0.86
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Mol Med Rep (2010) 0.86
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res (2011) 0.86
In vitro metabonomic study detects increases in UDP-GlcNAc and UDP-GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. J Proteome Res (2011) 0.85
Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells. NMR Biomed (2010) 0.85
Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks. Cancer Res (1997) 0.85
NMR-based metabolomic analysis of human bladder cancer. Anal Sci (2012) 0.85
The depletion of protein signals in metabonomics analysis with the WET-CPMG pulse sequence. Biochem Biophys Res Commun (2003) 0.84
Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics. Biochem Pharmacol (2010) 0.84
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol Oncol (2012) 0.83
Study of a novel indolin-2-ketone compound Z24 induced hepatotoxicity by NMR-spectroscopy-based metabonomics of rat urine, blood plasma, and liver extracts. Toxicol Appl Pharmacol (2006) 0.82
Genetic algorithms for simultaneous variable and sample selection in metabonomics. Bioinformatics (2008) 0.81
Locoregional administration of 5-fluoro-2'-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy. J Cancer Res Clin Oncol (1991) 0.81
A case report - Volatile metabolomic signature of malignant melanoma using matching skin as a control. J Cancer Sci Ther (2011) 0.81
Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors. Digestion (2013) 0.80
Targeting the HER2 receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther (2012) 0.79
Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. Clin Colorectal Cancer (2011) 0.78
Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. Carbohydr Res (2005) 0.76